Dr Bardia on the Continued Investigation of Elacestrant in ER+/HER2– Breast Cancer
November 15th 2023
Aditya Bardia, MD, MPH, discusses the continued investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.